MFLRC
Licensing and regulatory updates from our consultants.
July 5, 2026 · Pharmaceuticals
The FDA now holds sponsors accountable when their contract manufacturer, packager, or testing lab fails. Here is what binding quality agreements, supplier audits, and oversight your company needs across pharma, NHP, and devices in 2026.
#FDA
By Mussarat Fatima
July 5, 2026 · Regulatory Affairs
Health Canada's amended drug and device shortage framework (SOR/2026-96) took effect on 17 June 2026. Here is what is law now, what is only proposed, and the ten steps market authorization holders should take.
#Health Canada
By Mussarat Fatima
July 5, 2026 · GMP
On 22 April 2026 the United States moved medical and FDA-approved marijuana to Schedule III. Here is what the two-tier reform means for tax, banking, research and cannabis compliance, and how businesses should prepare.
#Cannabis
By Mussarat Fatima
July 3, 2026 · Regulatory Affairs
Health Canada's proposed Foreign Reliance Order (the Ministerial Reliance Order) could speed drug approvals by relying on trusted foreign regulators. Learn the three pathways, who qualifies, and how to prepare a reliance submission.
#Health Canada
By Mussarat Fatima
July 3, 2026 · Natural Health Products
Health Canada's Red Tape Review will simplify natural health product licensing and post-market obligations. Learn the likely changes, the timeline, and how NHP companies should prepare for a risk-based model now.
#Natural Health Products
By Mussarat Fatima
July 2, 2026 · Regulatory Affairs
Health Canada will formally accept PACMPs for biologic and radiopharmaceutical (BRDD) products after the 90-day ICH Q12 transition ends August 13, 2026. Here is what qualifies, how the two-step PACMP works, and how to prepare.
#Health Canada
By Mussarat Fatima
July 2, 2026 · Regulatory Affairs
A cross-border guide to inspection responses that hold up. What the FDA's March 2026 Form 483 draft guidance requires, how Health Canada's Exit Notice and CAPA process works, and how to keep a finding from escalating into a warning letter or licence action.
#FDA
By Mussarat Fatima
June 30, 2026 · Quality Assurance
The FDA's first AI warning letter (Purolea) shows the risk of unreviewed AI records. A practical framework to use AI in GMP documentation with human review, CSV and data integrity, for pharma, NHP, cosmetics and cannabis.
#Artificial Intelligence
By Mussarat Fatima
June 29, 2026 · Pharmaceuticals
The EU-GMP Annex 15 revision will make qualification and validation mandatory for chemical and biological active substance (API) manufacturers, not just finished-product sites. A joint EMA and PIC/S concept paper set the direction, consultation closed in April 2026, and the final text is targeted for publication by December 2026. Here is what the timeline means and how API sites should prepare.
#EU-GMP
By Mussarat Fatima
June 29, 2026 · Pharmaceuticals
The FDA issued 25 warning letters in June 2026 over false or misleading promotion of compounded GLP-1 products. Here is what telehealth, pharmaceutical, and natural health product companies must fix, in the United States and Canada, to stay compliant.
#GLP-1
By Mussarat Fatima
June 27, 2026 · Food and Beverages
On June 25, 2026, the CFIA released its Food Fraud Annual Report 2024 to 2025: 886 authenticity samples tested and more than 150,000 kg of misrepresented food kept off the market. Olive oil had the lowest authenticity compliance and imported honey drove most of the seized volume. Here is what the findings mean for food manufacturers, importers and co-packers, and how to build food fraud controls into your compliance program.
#Food Fraud
By Mussarat Fatima
June 27, 2026 · Pharmaceuticals
Health Canada's revised nitrosamine guidance changes the notification trigger and updates Acceptable Intake limits. Here is what pharmaceutical MAHs must do now to stay compliant.
#Nitrosamine Impurities
By Mussarat Fatima
June 24, 2026 · Food and Beverages
Canada's supplemented foods transition period ended December 31, 2025. CFIA is now verifying Division 29 labels. Here is what a compliant label requires and where to start.
#Supplemented Foods
By Mussarat Fatima
June 23, 2026 · GMP
A practical guide to Health Canada cultivation licence requirements after SOR/2025-43, covering licence classes, the 800 square metre micro limit, security clearances, GPP and the CTLS application path.
#Cannabis
By Mussarat Fatima
June 23, 2026 · Pharmaceuticals
ICH Q1 is being rewritten. One consolidated guideline will replace Q1A-F and Q5C, extend stability testing to biologics and advanced therapies, and tie stability to the product lifecycle. Here is what changes for your stability program.
#Stability Testing
By Mussarat Fatima
June 23, 2026 · GMP
Cannabis licensing in the United States runs state by state while federal law shifts. This guide covers licence types, the April 2026 Schedule III order, new hemp THC limits and how to build a strong application.
#Cannabis
By Mussarat Fatima
June 22, 2026 · Regulatory Affairs
Health Canada has proposed a Ministerial Order to exempt low-risk non-prescription drugs and sunscreens from the new-drug pathway. Here is what it covers, where the compliance risks sit, and how to comment by July 14, 2026.
#Non-prescription Drugs
By Mussarat Fatima
June 21, 2026 · Compliance
Texas expanded its Compassionate Use Program in 2025 under HB 46, adding 12 new dispensing organization licences. Here is how the Texas cannabis licence works, who can apply, and what a competitive application requires.
#Cannabis
By Mussarat Fatima
June 20, 2026 · Compliance
A current guide to natural health product compliance in Canada, covering product and site licensing, GMP, Vanessa's Law enforcement, modernized labelling and cost recovery.
#Natural Health Products
By Mussarat Fatima
June 20, 2026 · Cultivation
Integrated Pest Management protects cannabis crops without putting your licence at risk. This 2026 guide covers action thresholds, monitoring, prevention and controls, plus the Health Canada pesticide rules and mandatory testing every licensed producer must meet.
#Cannabis
By Mussarat Fatima
June 20, 2026 · Compliance
A practical, up-to-date guide to labelling compliance in Canada across food, cannabis and natural health products, with 10 ways to prevent costly label errors and recalls.
#Food Labelling
By Mussarat Fatima
June 20, 2026 · Cultivation
Sensory evaluation is a frontline quality control tool for cannabis. Learn how appearance, aroma and texture checks support Health Canada compliance, how they differ from lab testing, and how to build a defensible program.
#Cannabis
By Mussarat Fatima
June 20, 2026 · Medical Device
The FDA's Quality Management System Regulation replaced the QSR on February 2, 2026 and built 21 CFR Part 820 on ISO 13485:2016. Here is what changed, what records FDA can now inspect, and the steps device makers should take to stay compliant.
#FDA
By Mussarat Fatima
June 19, 2026 · Compliance
How experienced cannabis licensing consultants help Canadian licence holders streamline Health Canada compliance, from licensing and SOPs to audits, CTLS reporting and QAP support.
#Cannabis
By Mussarat Fatima
June 19, 2026 · Compliance
A practical, up to date guide to passing a Health Canada cannabis inspection, built around the latest 2025 to 2026 inspection data, the March 2025 rule changes, Good Production Practices, recordkeeping and the right way to handle CAPA.
#Cannabis
By Mussarat Fatima
June 19, 2026 · Regulatory Affairs
Health Canada's MDEL Phase II amendments (SOR/2026-110) take effect December 14, 2026. A practical guide to the foreign distributor exemption, the mandatory supplier list, and the new documented-procedure rules for medical device importers and distributors.
#Health Canada
By Mussarat Fatima
June 19, 2026 · Pharmaceuticals
Data integrity appears in 60-80% of FDA drug GMP warning letters. See the 2026 findings, the ALCOA+ controls that prevent them, and how MFLRC supports gap assessments, audit-trail review, CSV, and CAPA.
#Data Integrity
By Mussarat Fatima
June 18, 2026 · Quality Assurance
A practical, cross-sector guide to writing Health Canada SOPs for cannabis, drugs, NHPs, medical devices and food, with the ALCOA+ standard, common findings and an inspection-ready checklist.
#Health Canada
By Mussarat Fatima
June 18, 2026 · Medical Device
Canada's Phase II MDEL amendments (SOR/2026-110) take effect December 14, 2026. Foreign distributors selling through a licensed Canadian importer no longer need their own MDEL, while supplier lists and documented procedures become mandatory. Here is what importers and distributors must do now.
#Medical Devices
By Mussarat Fatima
June 18, 2026 · Compliance
EU-GMP certification is the key that unlocks Europe for Canadian cannabis producers. This 2026 guide covers the certification process, GACP, GMP and GDP, timelines, a compliance checklist and the most common mistakes to avoid.
#EU-GMP
By Mussarat Fatima
June 17, 2026 · Quality Assurance
Fully documented sterile sites still fail Annex 1 because they cannot show continuous, connected contamination control. Here is how to build an inspection-ready CCS.
#Pharmaceuticals
By Mussarat Fatima
June 16, 2026 · Good Production Practices
Edible cannabis and cannabis extracts look similar but face very different rules. Learn how Health Canada classifies ingestible cannabis products, the 10 mg and 1,000 mg THC limits, the food-format test, and how to stay compliant.
#Cannabis
By Mussarat Fatima
June 16, 2026 · Compliance
Health Canada conducted 889 cannabis inspections in 2024-2025, and the same compliance gaps keep showing up. Learn the top five mistakes licensed producers make, what current inspection data reveals, and the practical fixes that keep you inspection-ready.
#Cannabis
By Mussarat Fatima
June 16, 2026 · Regulatory Affairs
The European Commission, EMA and PIC/S published draft revisions of Annex 11 and Chapter 4 and a brand new Annex 22 on artificial intelligence on 7 July 2025. Finals are expected mid-2026. Here is what changes and how to get ready.
#Compliance
By Mussarat Fatima
June 15, 2026 · License
A cannabis business plan in Canada is not just an investor document. It is the blueprint that proves to Health Canada you can operate safely and legally. This 2026 guide covers licence classes, the CTLS, market data, the quality and compliance backbone, financials and the mistakes that sink applications.
#Cannabis
By Mussarat Fatima
June 15, 2026 · Food and Beverages
The CFIA will inspect more than 2,400 licensed-but-uninspected manufactured-food establishments by fall 2026. Here is what the expanded Preventive Control Plan, chemical hazard and food safety culture expectations mean for SFC licence-holders, and how to be inspection-ready.
#CFIA
By Mussarat Fatima
June 15, 2026 · Regulatory Affairs
The FDA's first warning letter to cite AI misuse (Purolea, 21 CFR 211.22(c)). What it means for your Quality Unit and how to govern AI in a GMP environment.
#Pharmaceuticals
By Mussarat Fatima
June 14, 2026 · Regulatory Affairs
Canadian producers supplied 53 percent of Germany medical cannabis imports in Q1 2026. This 2026 roadmap maps the EU-GMP and GACP certification path Canadian LPs need to reach the German pharmacy channel, from gap analysis to overseas inspection.
#Cannabis
By Mussarat Fatima
June 13, 2026 · Regulatory Affairs
State-licensed U.S. medical marijuana operators must file for DEA registration by June 22, 2026 to keep operating, and the expedited Schedule III hearing runs June 29 to July 15. Here is what it means for U.S. operators and Canadian LPs.
#Controlled Substances
By Mussarat Fatima
June 13, 2026 · Natural Health Products
Health Canada's GUI-0158 Version 4.0 came into force March 4, 2026. A compliance checklist, QAP responsibility matrix, and FAQ for Canadian NHP licence holders and importers.
#GUI-0158
By Mussarat Fatima
June 12, 2026 · Regulatory Affairs
ICH E6(R3) Annex 2 was adopted at Step 4 on 3 June 2026, completing the modern GCP framework. Here is how Canadian sponsors and sites can get decentralized trial and real-world data compliance ready before Health Canada's 1 October 2026 deadline.
#Health Canada
By Mussarat Fatima
June 12, 2026 · Regulatory Affairs
Health Canada's new terms and conditions framework takes effect April 1, 2027, replacing the NOC/c pathway. A practical guide to agile licensing and lifecycle obligations for sponsors.
#Health Canada
By Mussarat Fatima
June 11, 2026 · Regulatory Affairs
Health Canada's April 2026 pre-market guidance for machine learning-enabled medical devices introduces the Predetermined Change Control Plan (PCCP). Here is what Canadian manufacturers need to know about data quality, bias management and licensing.
#Health Canada
By Mussarat Fatima
June 11, 2026 · Regulatory Affairs
The biggest rewrite of EU GMP Annex 11 since 2011 lands mid-2026: 17 chapters covering validation, audit trails, supplier oversight, cybersecurity and a new Annex 22 on AI. Here is the gap assessment roadmap for Canadian exporters to the EU.
#Compliance
By Mussarat Fatima
June 10, 2026 · Regulatory Affairs
The revised EU-GMP Chapter 4 is format-neutral: photos, video and real-time feeds now count as GMP records. Learn what data-integrity controls your site needs before mid-2026.
#Pharmaceuticals
By Mussarat Fatima
June 9, 2026 · Regulatory Affairs
The FDA's 2026 CDER agenda adds guidance on distributed manufacturing, AI/ML quality, PET drug CGMP, and Form 483 responses. Here is what Canadian exporters should do now.
#Pharmaceuticals
By Mussarat Fatima
June 8, 2026 · Regulatory Affairs
How psychedelic-assisted therapy is regulated in Canada in 2025: the three legal pathways (clinical trials, the Special Access Program, and Section 56 exemptions), the controlled-substance rules for psilocybin and MDMA, and what the Toth v. Canada Federal Court ruling means for practitioner training.
#Health Canada
By Mussarat Fatima
June 7, 2026 · Regulations
Health Canada is consulting on major reforms to the Industrial Hemp Regulations, including possibly dropping licence requirements for some activities. Comments close June 30, 2026. Here is what is proposed, who benefits, and how to write a submission that gets read.
#Cannabis
By Mussarat Fatima
June 5, 2026 · Regulatory Affairs
From April 2026, Canadian cosmetics can no longer hide key fragrance allergens behind the word "parfum." A practical roadmap: what changed, how to read supplier allergen certificates, updating labels and CNFs, and what the 2026 Hotlist proposals mean for your formulas.
#Health Canada
By Mussarat Fatima
June 3, 2026 · Regulatory Affairs
By 2026, EU GMP Annex 1 is fully in force and firmly enforced. Any Canadian pharmaceutical manufacturer or cannabis Licensed Producer exporting sterile or EU-GMP product to the EU or UK must have a documented, living Contamination Control Strategy (CCS) ready for inspection—or risk critical findings and loss of market access.
#Health Canada
By Mussarat Fatima
June 2, 2026 · Regulations
Cannabis excise tax reform in Canada is gaining momentum. The Expert Panel's final report urged a review of the $1/gram excise floor and potency-based duties, a 2025 Deloitte report sharpened the case, and micro-class limits have already quadrupled. Here's what could change for licensed producers and how to prepare.
#Cannabis
By Mussarat Fatima
June 1, 2026 · Regulatory Affairs
ICH E6(R3) Good Clinical Practice has been in force in Canada since 1 April 2026, with the transition period closing 30 September 2026. A verified quality-by-design and risk-proportionality readiness plan for sponsors, CROs, and sites.
#Health Canada
By Mussarat Fatima
May 24, 2026 · Regulatory Affairs
Health Canada's April 2026 Final Notice (following its 14 August 2025 consultation Notice) clarifies how exosome, extracellular vesicle, and cell-conditioned media topical products are classified at the cosmetic-drug interface. Learn the three statutory considerations, MFLRC's six-trigger framework, the cosmetic/NHP/drug/biologic decision tree, and a reformulation checklist for skin-care, hair-care, and medi-aesthetic brands.
#Exosomes
By Mussarat Fatima
May 21, 2026 · Food and Beverages
As of January 1, 2026, Health Canada’s Front-of-Package (FOP) nutrition symbol is mandatory on prepackaged foods and beverages that are high in saturated fat, sugars, or sodium. Learn what the new rules require, who must comply, key exemptions, and how to complete a defensible FOP readiness assessment for your full SKU portfolio.
#FOP Nutrition Labelling
By Mussarat Fatima
May 20, 2026 · Natural Health Products
Health Canada's new NHP GMP Guide (GUI-0158, Version 4.0) came into force on March 4, 2026. It introduces real-time stability expectations, evidenced importer oversight, and a full quality-systems approach. Here is what Canadian NHP licence holders need to do now to stay inspection-ready.
#GUI-0158
By Mussarat Fatima
May 19, 2026 · Regulatory Affairs
A practical breakdown of SOR/2025-242 — Canada's new Controlled Substances Regulations. Monthly reporting, unified dealer licensing, October 1, 2026 deadline, and what manufacturers and dealers must do now.
#SOR/2025-242
By Mussarat Fatima
May 11, 2026 · Medical Device
EUDAMED is no longer optional. From 28 May 2026, the first four modules become mandatory for every economic operator selling devices into the EU. Here's the pre-flight checklist MDEL holders and EU manufacturers should already be running.
#EUDAMED
By Mussarat Fatima
May 8, 2026 · Compliance
The DEA's April 28 Schedule III order reshapes cross-border cannabis. Canadian LPs: here's what 280E elimination, M&A, and the June 27 deadline mean for your quality system — and your next capital raise.
#DEA, Schedule III, 280E, Canadian LP, Quality Systems, Cannabis M&A, Health Canada, GMP, Pharmaceutical Validation, Regulatory Affairs
By Mussarat Fatima
May 5, 2026 · Compliance
Learn how to comply with Health Canada’s 2026 cannabis sampling guidance, including storage, security, record-keeping, and provincial rules for retailer samples.
By Mussarat Fatima
March 29, 2026 · Regulations
Discover how new cannabis regulations in Canada simplify compliance for licence holders, boost competition, and enhance the market—find out more!
By Mussarat Fatima
March 29, 2026 · Compliance
Learn how cannabis licensing consultants can help Canadian cannabis businesses streamline compliance with expert knowledge, comprehensive SOPs, audits, tracking and reporting systems, and more. Get insights from industry experts and stay ahead of changing regulations.
By Mussarat Fatima
March 19, 2026 · Cannabis regulations, label, Quality assurance,
By Mussarat Fatima
December 8, 2025 · Good Production Practices
Good Production Practices (GPP) are the legal foundation of every federal cannabis licence in Canada. This guide explains the Part 5 requirements, the QAP role, GPP versus EU-GMP, and how to stay inspection-ready.
#Good Production Practices
By Mussarat Fatima
October 3, 2025 · Compliance
By Mussarat Fatima
September 30, 2025 · Compliance
A first grower's guide to trimming cannabis at the right time, from vegetative pruning to post-harvest, with the compliance steps licensed producers need.
#Cannabis
By Mussarat Fatima
September 19, 2025 · Compliance
By Mussarat Fatima
September 12, 2025 · Good Production Practices
By Mussarat Fatima
August 28, 2025 · Compliance
By Mussarat Fatima
August 25, 2025 · Compliance
By Mussarat Fatima
August 19, 2025 · Compliance
By Mussarat Fatima
August 16, 2025 · Compliance
By Mussarat Fatima
August 13, 2025 · Compliance
By Mussarat Fatima
August 12, 2025 · Compliance
By Mussarat Fatima
August 12, 2025 · Compliance
By Mussarat Fatima
August 12, 2025 · Compliance
By Mussarat Fatima
August 12, 2025 · Compliance
By Mussarat Fatima
August 7, 2025 · Regulatory Affairs
A regulatory dossier is the organized evidence that turns a product into an approved product. Learn what a dossier is, the main types across pharma, cannabis, NHP, food, cosmetics and devices, and how to prepare one.
#Compliance
By Mussarat Fatima
August 1, 2025 · GMP
By Mussarat Fatima
June 21, 2025 · GMP
Selling cannabis legally in Canada takes more than one licence. This guide maps the Health Canada licence classes, the CRA excise layer, provincial retail rules and the daily compliance obligations that keep a licence alive.
#Cannabis
By Mussarat Fatima
June 18, 2025 · License
Farmgate and retail cannabis licences follow very different rules in Canada. This guide explains who can apply, how Ontario, British Columbia and Alberta structure their programs, and what compliance looks like after opening.
#Cannabis
By Mussarat Fatima
June 15, 2025 · Good Production Practices
A step-by-step guide to building a compliant cannabis analytical testing lab in Canada, from the licence for analytical testing and head of laboratory to validated methods, equipment, and ISO/IEC 17025 accreditation.
#Analytical Testing
By Mussarat Fatima
June 12, 2025 · Good Production Practices
Build a cannabis QA compliance checklist that satisfies Health Canada Good Production Practices, from QAP oversight and mandatory testing to recalls and inspection readiness.
#Cannabis
By Mussarat Fatima
June 9, 2025 · License
Cannabis retail rules change at every provincial border. A senior consultant's guide to how provincial cannabis licences differ across Canada and how to plan for multi-province expansion.
#Cannabis
By Mussarat Fatima
June 6, 2025 · License
A senior consultant's guide to the cannabis licence application mistakes that stall Health Canada approval, and how to build a CTLS submission that clears review the first time.
#Cannabis
By Mussarat Fatima
June 3, 2025 · Compliance
A Health Canada inspection rewards everyday discipline, not last-minute cramming. Here is what inspectors check, the findings that trip producers up, and how to stay audit-ready every day.
#Cannabis
By Mussarat Fatima
September 25, 2024 · GMP
In Canada, cannabis producers follow Good Production Practices, while EU-GMP certification unlocks export markets like Germany. Here is what GMP certification involves, what it costs, and how to prepare.
#Cannabis
By Mussarat Fatima
July 2, 2024 · Cannabis regulations, label, Quality assurance,
By Mussarat Fatima
June 10, 2024 · Compliance
Unlock the secrets of superior cannabis production hygiene with our latest blog post. Dive into GMP's rigorous cleaning protocols for braided stainless-steel cables, guaranteeing unparalleled quality and safety in every cannabis product. Elevate your industry knowledge and stay ahead of the curve today!
By Mussarat Fatima
December 19, 2023 · License
A cannabis research licence is how universities, companies and clinicians legally study cannabis in Canada. This guide explains the licence types, the CTLS application process, NTRC and clinical-trial rules, and how to build an approvable file.
#Cannabis Research
By Mussarat Fatima
December 4, 2023 · Compliance
By Mussarat Fatima
November 27, 2023 · License
By Mussarat Fatima
October 17, 2023 · Cultivation
Five years after Canada legalized cannabis in October 2018, we review the achievements and the ongoing challenges, from economic growth and public health to youth use, impaired driving and pricing.
#Cannabis
By Mussarat Fatima
March 23, 2023 · Compliance
Quality assurance is not optional for Canadian cannabis licence holders. Here is what QA involves under current Health Canada rules, the real risks of cutting corners, and a practical compliance checklist.
#Cannabis
By Mussarat Fatima
October 5, 2022 · Good Production Practices
Root cause analysis drives effective CAPA. Learn the 11 mistakes that make investigations fail in cannabis and GMP facilities, and how to avoid each one.
#Cannabis
By Mussarat Fatima
September 9, 2022 · Good Production Practices
Cannabis recalls are preventable quality failures. Here are nine practical ways to avoid them, plus Health Canada recall types, timelines, and mock recall rules.
#Cannabis
By Mussarat Fatima
September 9, 2022 · License
A practical, up to date guide to opening and operating a cannabis retail store or farmgate in Ontario, covering AGCO licences, OCS wholesale, store rules, fees, staff training and the compliance habits that keep your authorization in good standing.
#Cannabis
By Mussarat Fatima
September 8, 2022 · Compliance
Ten practical essentials for cannabis compliance in Canada, from building a compliance team and internal audits to marketing rules, provincial age limits and recordkeeping.
#Cannabis
By Mussarat Fatima
September 8, 2022 · Compliance
Internal audits help Canadian cannabis, pharma and NHP producers find and fix compliance gaps before Health Canada does. Learn the process, checklist and best practices.
#Cannabis
By Mussarat Fatima
